Arvinas (NASDAQ:ARVN) Stock Rating Lowered by Leerink Partnrs

Arvinas (NASDAQ:ARVN - Get Free Report) was downgraded by stock analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating in a note issued to investors on Sunday,Zacks.com reports. Leerink Partnrs also issued estimates for Arvinas' Q2 2025 earnings at $0.26 EPS, Q3 2025 earnings at ($0.44) EPS, Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at $0.66 EPS, FY2026 earnings at ($2.22) EPS and FY2027 earnings at ($2.52) EPS.

Other research analysts also recently issued research reports about the company. Guggenheim dropped their price target on Arvinas from $32.00 to $16.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. Stifel Nicolaus dropped their price target on Arvinas from $63.00 to $51.00 and set a "buy" rating for the company in a research note on Wednesday, February 12th. Wedbush cut Arvinas from an "outperform" rating to a "neutral" rating and decreased their target price for the company from $57.00 to $12.00 in a research report on Wednesday, March 12th. Leerink Partners reiterated a "market perform" rating and issued a $9.00 target price (down previously from $10.00) on shares of Arvinas in a research report on Monday. Finally, Jefferies Financial Group reiterated a "hold" rating and issued a $10.00 target price (down previously from $52.00) on shares of Arvinas in a research report on Friday, May 2nd. Ten analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $20.29.

Arvinas Price Performance

ARVN stock traded down $0.05 during midday trading on Friday, reaching $6.95. The company had a trading volume of 1,569,460 shares, compared to its average volume of 1,383,278. The company has a market capitalization of $507.29 million, a price-to-earnings ratio of -2.51 and a beta of 2.21. The stock has a 50 day moving average price of $7.28 and a 200-day moving average price of $14.40. Arvinas has a 1-year low of $5.90 and a 1-year high of $34.11.

Arvinas (NASDAQ:ARVN - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported $1.14 EPS for the quarter, beating analysts' consensus estimates of ($0.93) by $2.07. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. The business's revenue was up 646.2% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.97) earnings per share. As a group, research analysts anticipate that Arvinas will post -3.81 earnings per share for the current year.

Insider Activity at Arvinas

In other Arvinas news, insider Noah Berkowitz sold 8,658 shares of the business's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.59, for a total value of $74,372.22. Following the transaction, the insider now directly owns 110,023 shares of the company's stock, valued at approximately $945,097.57. The trade was a 7.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.73% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Arvinas

Institutional investors have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. acquired a new position in Arvinas in the fourth quarter valued at approximately $28,000. KBC Group NV lifted its stake in Arvinas by 77.0% in the fourth quarter. KBC Group NV now owns 2,885 shares of the company's stock valued at $55,000 after buying an additional 1,255 shares during the period. GAMMA Investing LLC lifted its stake in Arvinas by 11,283.8% in the first quarter. GAMMA Investing LLC now owns 4,212 shares of the company's stock valued at $300,000 after buying an additional 4,175 shares during the period. Caitong International Asset Management Co. Ltd lifted its stake in Arvinas by 965.4% in the first quarter. Caitong International Asset Management Co. Ltd now owns 4,656 shares of the company's stock valued at $33,000 after buying an additional 4,219 shares during the period. Finally, CWM LLC lifted its stake in Arvinas by 2,317.5% in the first quarter. CWM LLC now owns 7,615 shares of the company's stock valued at $53,000 after buying an additional 7,300 shares during the period. 95.19% of the stock is owned by institutional investors and hedge funds.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.